false000086073000008607302025-01-242025-01-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): January 24, 2025 |
HCA Healthcare, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-11239 |
27-3865930 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
One Park Plaza |
|
Nashville, Tennessee |
|
37203 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (615) 344-9551 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value per share |
|
HCA |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 24, 2025, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2024, the text of which is set forth as Exhibit 99.1.
Item 7.01. Regulation FD Disclosure.
On January 24, 2025, the Company issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2024, the text of which is set forth as Exhibit 99.1.
Item 8.01. Other Events.
On January 24, 2025, the Company announced that its Board of Directors had authorized an additional share repurchase program for up to $10 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws from time to time in the open market, through privately negotiated transactions, or otherwise.
On January 24, 2025, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.72 per share of the Company’s common stock. The dividend will be paid on March 31, 2025 to stockholders of record at the close of business on March 17, 2025.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
HCA HEALTHCARE, INC. |
|
|
|
|
Date: |
January 24, 2025 |
By: |
/s/ Michael A. Marks |
|
|
|
Michael A. Marks Executive Vice President and Chief Financial Officer |
FOR IMMEDIATE RELEASE
|
|
|
INVESTOR CONTACT: |
|
MEDIA CONTACT: |
Frank Morgan |
|
Harlow Sumerford |
615-344-2688 |
|
615-344-1851 |
HCA Healthcare reports FOURTH quarter 2024 results
AND PROVIDES 2025 GUIDANCE
Nashville, Tenn., January 24, 2025 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the fourth quarter ended December 31, 2024.
Key fourth quarter metrics (all percentage changes compare 4Q 2024 to 4Q 2023 unless otherwise noted):
•Revenues totaled $18.285 billion
•Net income attributable to HCA Healthcare, Inc. totaled $1.438 billion, or $5.63 per diluted share (which includes an estimated $0.60 per diluted share unfavorable impact from Hurricanes Helene and Milton)
•Adjusted EBITDA totaled $3.712 billion
•Cash flows from operating activities totaled $2.559 billion
•Same facility admissions increased 3.0 percent and same facility equivalent admissions increased 3.1 percent
"We finished 2024 with strong business fundamentals that were consistent with previous quarters," said Sam Hazen, Chief Executive Officer of HCA Healthcare. "The first half of the current decade, which ended in 2024, proved to be another period of long-term growth for the company and resulted in operational improvements across key performance indicators and greater value for our patients, employees and shareholders. These accomplishments are a testament to the incredible work of our teams, and position us well for the future."
Revenues in the fourth quarter of 2024 totaled $18.285 billion, compared to $17.303 billion in the fourth quarter of 2023. Net income attributable to HCA Healthcare, Inc. totaled $1.438 billion, or $5.63 per diluted share, compared to $1.607 billion, or $5.93 per diluted share, in the fourth quarter of 2023. Results for the fourth quarter of 2024 include losses on sales of facilities of $195 million, or $0.59 per diluted share, primarily related to the pending sale of a hospital facility in California. Results for the fourth quarter of 2023 include gains on sales of facilities of $7 million, or $0.03 per diluted share.
For the fourth quarter of 2024, Adjusted EBITDA totaled $3.712 billion, compared to $3.618 billion in the fourth quarter of 2023. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.
Same facility admissions increased 3.0 percent and same facility equivalent admissions increased 3.1 percent in the fourth quarter of 2024, compared to the prior year period. Same facility emergency room visits increased 2.4 percent in the fourth quarter of 2024, compared to the prior year period. Same facility inpatient surgeries increased 2.8 percent, and same facility outpatient surgeries declined 1.3 percent in the fourth quarter of 2024, compared to the same period of 2023. Same facility revenue per equivalent admission increased 2.9 percent in the fourth quarter of 2024, compared to the fourth quarter of 2023.
Year Ended December 31, 2024
Revenues for the year ended December 31, 2024 totaled $70.603 billion, compared to $64.968 billion for the year ended December 31, 2023. Net income attributable to HCA Healthcare, Inc. was $5.760 billion, or $22.00 per diluted share, compared to $5.242 billion, or $18.97 per diluted share, for the year ended December 31, 2023. Results for the year ended December 31, 2024 include gains on sales of facilities of $14 million, or $0.04 per diluted share. Results for the year ended December 31, 2023 included losses on sales of facilities of $5 million, or $0.04 per diluted share.
For 2024, Adjusted EBITDA totaled $13.882 billion, compared to $12.726 billion in 2023. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.
Balance Sheet and Cash Flows from Operations
As of December 31, 2024, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $1.933 billion, total debt of $43.031 billion, and total assets of $59.513 billion. During the fourth quarter of 2024, capital expenditures totaled $1.285 billion, excluding acquisitions. Cash flows provided by operating activities in the fourth quarter of 2024 totaled $2.559 billion, compared to $2.674 billion in the fourth quarter of 2023.
During the fourth quarter of 2024, the Company repurchased 4.739 million shares of its common stock at a cost of $1.700 billion. The Company had $764 million remaining under its repurchase authorization as of December 31, 2024. As of December 31, 2024, the Company had $7.986 billion of availability under its credit facilities.
Share Repurchase Program
The HCA Healthcare, Inc. Board of Directors has authorized an additional share repurchase program for up to $10 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws and may be made at management’s discretion from time to time in the open market, through privately negotiated transactions, or otherwise. The repurchase program has no time limit and may be suspended for periods or discontinued at any time.
Dividend
HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.72 per share on the Company’s common stock. The dividend will be paid on March 31, 2025 to stockholders of record at the close of business on March 17, 2025.
The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition, results of operations, and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.
Impact of Hurricanes
During the fourth quarter of 2024, the Company incurred additional expenses and experienced loss of revenues estimated at $200 million, or $0.60 per diluted share, associated with Hurricane Helene's impact on its North Carolina facilities, as well as from Hurricane Milton, which impacted certain facilities in Florida.
For the year ended December 31, 2024, the Company incurred additional expenses and experienced loss of revenues estimated at $250 million, or $0.73 per diluted share, associated with the impact of Hurricanes Helene and Milton on the Company's North Carolina facilities and certain facilities in Florida.
These estimates do not include any insurance recoveries the Company may receive. All facilities impacted by Hurricanes Helene and Milton have resumed normal operations.
2025 Guidance
Today, the Company issued the following estimated guidance for 2025:
|
|
|
|
|
|
2025 Guidance Range |
Revenues |
|
$72.80 to $75.80 billion |
Net Income Attributable to HCA Healthcare, Inc. |
|
$5.85 to $6.29 billion |
Adjusted EBITDA |
|
$14.30 to $15.10 billion |
EPS (diluted) |
|
$24.05 to $25.85 per diluted share |
Capital expenditures for 2025, excluding acquisitions, are estimated to be approximately $5.0 to $5.2 billion.
The Company’s guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding volume growth coupled with an anticipated mostly stable operating environment, payer mix, and the ongoing impacts of the two major hurricanes, the impact of current and future health care public policy developments, as well as general economic conditions, including inflation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.
Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.
The Company’s guidance is based on current plans and expectations and are subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”
Annual Stockholders' Meeting
The Company's 2025 annual stockholders' meeting will be held virtually on April 24, 2025 at 2:00 p.m. Central Time for stockholders of record as of February 24, 2025.
Earnings Conference Call
HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed through the Company’s Investor Relations web page at https://investor.hcahealthcare.com/events-and-presentations/default.aspx.
About the Company
As of December 31, 2024, HCA operated 190 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending December 31, 2025, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) changes in or related to general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions (and the impact thereof on the economy, financial markets and banking industry); changes in revenues due to declining patient volumes; changes in payer mix (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions; supply shortages and disruptions (including as a result of geopolitical disruptions); and the impact of potential federal government shutdowns, (2) the impact of our significant indebtedness and the ability to refinance such indebtedness on acceptable terms, (3) the impact of current and future health care public policy developments and possible changes to other federal, state or local laws and regulations affecting the health care industry, including, but not limited to, the expiration of enhanced premium tax credits for individuals eligible to purchase insurance coverage through federal and state-based health insurance marketplaces, (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, attain expected levels of patient volumes and revenues, and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs, Medicaid waiver programs or state directed payments, that may impact reimbursements to
health care providers and insurers and the size of the uninsured or underinsured population, (8) personnel-related capacity constraints, increases in wages and the ability to attract, utilize and retain qualified management and other personnel, including affiliated physicians, nurses and medical and technical support personnel, (9) the highly competitive nature of the health care business, (10) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (11) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (12) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) the emergence of and effects related to pandemics, epidemics and outbreaks of infectious diseases or other public health crises, (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) the impact of known and unknown government investigations, litigation and other claims that may be made against us, (21) the impact of actual and potential cybersecurity incidents or security breaches involving us or our vendors and other third parties, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record technology and the impact of interoperability requirements, (23) the impact of natural disasters, such as hurricanes and floods, including Hurricanes Milton and Helene, physical risks from climate change or similar events beyond our control on our assets and activities and the communities we serve, (24) changes in U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, (25) the results of our efforts to use technology and resilience initiatives, including artificial intelligence and machine learning, to drive efficiencies, better outcomes and an enhanced patient experience, (26) the impact of recent decisions of the U.S. Supreme Court regarding the actions of federal agencies, and (27) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2023 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.
HCA Healthcare, Inc.
Condensed Consolidated Comprehensive Income Statements
Fourth Quarter
Unaudited
(Dollars in millions, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
|
Amount |
|
|
Ratio |
|
|
|
Amount |
|
|
Ratio |
|
|
Revenues |
|
|
$ |
18,285 |
|
|
|
100.0 |
|
% |
|
$ |
17,303 |
|
|
|
100.0 |
|
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salaries and benefits |
|
|
|
7,917 |
|
|
|
43.3 |
|
|
|
|
7,570 |
|
|
|
43.7 |
|
|
Supplies |
|
|
|
2,793 |
|
|
|
15.3 |
|
|
|
|
2,584 |
|
|
|
14.9 |
|
|
Other operating expenses |
|
|
|
3,873 |
|
|
|
21.2 |
|
|
|
|
3,559 |
|
|
|
20.7 |
|
|
Equity in earnings of affiliates |
|
|
|
(10 |
) |
|
|
(0.1 |
) |
|
|
|
(28 |
) |
|
|
(0.2 |
) |
|
Depreciation and amortization |
|
|
|
856 |
|
|
|
4.6 |
|
|
|
|
789 |
|
|
|
4.5 |
|
|
Interest expense |
|
|
|
528 |
|
|
|
2.9 |
|
|
|
|
491 |
|
|
|
2.8 |
|
|
Losses (gains) on sales of facilities |
|
|
|
195 |
|
|
|
1.1 |
|
|
|
|
(7 |
) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,152 |
|
|
|
88.3 |
|
|
|
|
14,958 |
|
|
|
86.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
|
|
2,133 |
|
|
|
11.7 |
|
|
|
|
2,345 |
|
|
|
13.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes |
|
|
|
447 |
|
|
|
2.5 |
|
|
|
|
484 |
|
|
|
2.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
1,686 |
|
|
|
9.2 |
|
|
|
|
1,861 |
|
|
|
10.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to noncontrolling interests |
|
|
|
248 |
|
|
|
1.3 |
|
|
|
|
254 |
|
|
|
1.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to HCA Healthcare, Inc. |
|
|
$ |
1,438 |
|
|
|
7.9 |
|
|
|
$ |
1,607 |
|
|
|
9.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
|
$ |
5.63 |
|
|
|
|
|
|
$ |
5.93 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing diluted earnings per share (millions) |
|
|
|
255.310 |
|
|
|
|
|
|
|
271.186 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income attributable to HCA Healthcare, Inc. |
|
|
$ |
1,429 |
|
|
|
|
|
|
$ |
1,673 |
|
|
|
|
|
HCA Healthcare, Inc.
Condensed Consolidated Comprehensive Income Statements
For the Years Ended December 31, 2024 and 2023
Unaudited
(Dollars in millions, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
Amount |
|
|
Ratio |
|
|
|
Amount |
|
|
Ratio |
|
|
Revenues |
|
$ |
70,603 |
|
|
|
100.0 |
|
% |
|
$ |
64,968 |
|
|
|
100.0 |
|
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salaries and benefits |
|
|
31,170 |
|
|
|
44.1 |
|
|
|
|
29,487 |
|
|
|
45.4 |
|
|
Supplies |
|
|
10,755 |
|
|
|
15.2 |
|
|
|
|
9,902 |
|
|
|
15.2 |
|
|
Other operating expenses |
|
|
14,819 |
|
|
|
21.0 |
|
|
|
|
12,875 |
|
|
|
19.8 |
|
|
Equity in earnings of affiliates |
|
|
(23 |
) |
|
|
— |
|
|
|
|
(22 |
) |
|
|
— |
|
|
Depreciation and amortization |
|
|
3,312 |
|
|
|
4.7 |
|
|
|
|
3,077 |
|
|
|
4.7 |
|
|
Interest expense |
|
|
2,061 |
|
|
|
2.9 |
|
|
|
|
1,938 |
|
|
|
3.0 |
|
|
Losses (gains) on sales of facilities |
|
|
(14 |
) |
|
|
— |
|
|
|
|
5 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
62,080 |
|
|
|
87.9 |
|
|
|
|
57,262 |
|
|
|
88.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
|
8,523 |
|
|
|
12.1 |
|
|
|
|
7,706 |
|
|
|
11.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes |
|
|
1,866 |
|
|
|
2.7 |
|
|
|
|
1,615 |
|
|
|
2.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
6,657 |
|
|
|
9.4 |
|
|
|
|
6,091 |
|
|
|
9.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to noncontrolling interests |
|
|
897 |
|
|
|
1.2 |
|
|
|
|
849 |
|
|
|
1.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to HCA Healthcare, Inc. |
|
$ |
5,760 |
|
|
|
8.2 |
|
|
|
$ |
5,242 |
|
|
|
8.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
$ |
22.00 |
|
|
|
|
|
|
$ |
18.97 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing diluted earnings per share (millions) |
|
|
261.806 |
|
|
|
|
|
|
|
276.412 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income attributable to HCA Healthcare, Inc. |
|
$ |
5,798 |
|
|
|
|
|
|
$ |
5,307 |
|
|
|
|
|
HCA Healthcare, Inc.
Condensed Consolidated Balance Sheets
Unaudited
(Dollars in millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
September 30, |
|
|
December 31, |
|
|
|
2024 |
|
|
2024 |
|
|
2023 |
|
ASSETS |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
1,933 |
|
|
$ |
2,888 |
|
|
$ |
935 |
|
Accounts receivable |
|
|
10,751 |
|
|
|
9,915 |
|
|
|
9,958 |
|
Inventories |
|
|
1,738 |
|
|
|
1,776 |
|
|
|
2,021 |
|
Other |
|
|
1,992 |
|
|
|
2,083 |
|
|
|
2,013 |
|
|
|
|
16,414 |
|
|
|
16,662 |
|
|
|
14,927 |
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, at cost |
|
|
62,514 |
|
|
|
61,750 |
|
|
|
58,548 |
|
Accumulated depreciation |
|
|
(33,100 |
) |
|
|
(32,703 |
) |
|
|
(30,833 |
) |
|
|
|
29,414 |
|
|
|
29,047 |
|
|
|
27,715 |
|
|
|
|
|
|
|
|
|
|
|
Investments of insurance subsidiaries |
|
|
569 |
|
|
|
553 |
|
|
|
477 |
|
Investments in and advances to affiliates |
|
|
662 |
|
|
|
705 |
|
|
|
756 |
|
Goodwill and other intangible assets |
|
|
10,093 |
|
|
|
9,982 |
|
|
|
9,945 |
|
Right-of-use operating lease assets |
|
|
2,131 |
|
|
|
2,201 |
|
|
|
2,207 |
|
Other |
|
|
230 |
|
|
|
309 |
|
|
|
184 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
59,513 |
|
|
$ |
59,459 |
|
|
$ |
56,211 |
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
4,276 |
|
|
$ |
4,235 |
|
|
$ |
4,233 |
|
Accrued salaries |
|
|
2,304 |
|
|
|
2,164 |
|
|
|
2,127 |
|
Other accrued expenses |
|
|
3,899 |
|
|
|
3,819 |
|
|
|
3,871 |
|
Long-term debt due within one year |
|
|
4,698 |
|
|
|
4,682 |
|
|
|
2,424 |
|
|
|
|
15,177 |
|
|
|
14,900 |
|
|
|
12,655 |
|
|
|
|
|
|
|
|
|
|
|
Long-term debt, less debt issuance costs and discounts of $369, $378 and $333 |
|
|
38,333 |
|
|
|
38,283 |
|
|
|
37,169 |
|
Professional liability risks |
|
|
1,544 |
|
|
|
1,584 |
|
|
|
1,557 |
|
Right-of-use operating lease obligations |
|
|
1,863 |
|
|
|
1,924 |
|
|
|
1,903 |
|
Income taxes and other liabilities |
|
|
2,041 |
|
|
|
1,982 |
|
|
|
1,867 |
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
|
Stockholders' deficit attributable to HCA Healthcare, Inc. |
|
|
(2,499 |
) |
|
|
(2,182 |
) |
|
|
(1,774 |
) |
Noncontrolling interests |
|
|
3,054 |
|
|
|
2,968 |
|
|
|
2,834 |
|
|
|
|
555 |
|
|
|
786 |
|
|
|
1,060 |
|
|
|
$ |
59,513 |
|
|
$ |
59,459 |
|
|
$ |
56,211 |
|
HCA Healthcare, Inc.
Condensed Consolidated Statements of Cash Flows
For the Years Ended December 31, 2024 and 2023
Unaudited
(Dollars in millions)
|
|
|
|
|
|
|
|
|
|
|
2024 |
|
|
2023 |
|
Cash flows from operating activities: |
|
|
|
|
|
|
Net income |
|
$ |
6,657 |
|
|
$ |
6,091 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
Increase (decrease) in cash from operating assets and liabilities: |
|
|
|
|
|
|
Accounts receivable |
|
|
(799 |
) |
|
|
(935 |
) |
Inventories and other assets |
|
|
334 |
|
|
|
(126 |
) |
Accounts payable and accrued expenses |
|
|
359 |
|
|
|
604 |
|
Depreciation and amortization |
|
|
3,312 |
|
|
|
3,077 |
|
Income taxes |
|
|
22 |
|
|
|
229 |
|
Losses (gains) on sales of facilities |
|
|
(14 |
) |
|
|
5 |
|
Amortization of debt issuance costs and discounts |
|
|
35 |
|
|
|
35 |
|
Share-based compensation |
|
|
360 |
|
|
|
262 |
|
Other |
|
|
248 |
|
|
|
189 |
|
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
10,514 |
|
|
|
9,431 |
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
Purchase of property and equipment |
|
|
(4,875 |
) |
|
|
(4,744 |
) |
Acquisition of hospitals and health care entities |
|
|
(266 |
) |
|
|
(635 |
) |
Sales of hospitals and health care entities |
|
|
328 |
|
|
|
193 |
|
Change in investments |
|
|
(115 |
) |
|
|
(112 |
) |
Other |
|
|
(5 |
) |
|
|
(19 |
) |
|
|
|
|
|
|
|
Net cash used in investing activities |
|
|
(4,933 |
) |
|
|
(5,317 |
) |
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
Issuances of long-term debt |
|
|
7,495 |
|
|
|
3,224 |
|
Net change in revolving credit facilities |
|
|
(1,880 |
) |
|
|
(1,020 |
) |
Repayment of long-term debt |
|
|
(2,410 |
) |
|
|
(909 |
) |
Distributions to noncontrolling interests |
|
|
(711 |
) |
|
|
(640 |
) |
Payment of debt issuance costs |
|
|
(67 |
) |
|
|
(31 |
) |
Payment of dividends |
|
|
(690 |
) |
|
|
(661 |
) |
Repurchase of common stock |
|
|
(6,042 |
) |
|
|
(3,811 |
) |
Other |
|
|
(277 |
) |
|
|
(246 |
) |
|
|
|
|
|
|
|
Net cash used in financing activities |
|
|
(4,582 |
) |
|
|
(4,094 |
) |
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
(1 |
) |
|
|
7 |
|
|
|
|
|
|
|
|
Change in cash and cash equivalents |
|
|
998 |
|
|
|
27 |
|
Cash and cash equivalents at beginning of period |
|
|
935 |
|
|
|
908 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
1,933 |
|
|
$ |
935 |
|
|
|
|
|
|
|
|
Interest payments |
|
$ |
1,938 |
|
|
$ |
1,892 |
|
Income tax payments, net |
|
$ |
1,844 |
|
|
$ |
1,386 |
|
HCA Healthcare, Inc.
Operating Statistics
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter |
|
|
For the Years Ended December 31, |
|
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
Operations: |
|
|
|
|
|
|
|
|
|
|
|
|
Number of Hospitals |
|
|
190 |
|
|
|
186 |
|
|
|
190 |
|
|
|
186 |
|
Number of Freestanding Outpatient Surgery Centers* |
|
|
124 |
|
|
|
124 |
|
|
|
124 |
|
|
|
124 |
|
Licensed Beds at End of Period |
|
|
49,985 |
|
|
|
49,588 |
|
|
|
49,985 |
|
|
|
49,588 |
|
Weighted Average Beds in Service |
|
|
42,705 |
|
|
|
42,072 |
|
|
|
42,633 |
|
|
|
41,873 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reported: |
|
|
|
|
|
|
|
|
|
|
|
|
Admissions |
|
|
559,170 |
|
|
|
544,554 |
|
|
|
2,236,595 |
|
|
|
2,130,728 |
|
% Change |
|
|
2.7 |
% |
|
|
|
|
|
5.0 |
% |
|
|
|
Equivalent Admissions |
|
|
1,007,623 |
|
|
|
974,561 |
|
|
|
3,990,085 |
|
|
|
3,788,434 |
|
% Change |
|
|
3.4 |
% |
|
|
|
|
|
5.3 |
% |
|
|
|
Revenue per Equivalent Admission |
|
$ |
18,146 |
|
|
$ |
17,755 |
|
|
$ |
17,695 |
|
|
$ |
17,149 |
|
% Change |
|
|
2.2 |
% |
|
|
|
|
|
3.2 |
% |
|
|
|
Inpatient Revenue per Admission |
|
$ |
19,737 |
|
|
$ |
18,992 |
|
|
$ |
19,050 |
|
|
$ |
18,201 |
|
% Change |
|
|
3.9 |
% |
|
|
|
|
|
4.7 |
% |
|
|
|
Patient Days |
|
|
2,691,710 |
|
|
|
2,674,331 |
|
|
|
10,826,574 |
|
|
|
10,483,236 |
|
% Change |
|
|
0.6 |
% |
|
|
|
|
|
3.3 |
% |
|
|
|
Equivalent Patient Days |
|
|
4,850,820 |
|
|
|
4,786,197 |
|
|
|
19,314,608 |
|
|
|
18,639,194 |
|
% Change |
|
|
1.4 |
% |
|
|
|
|
|
3.6 |
% |
|
|
|
Inpatient Surgery Cases |
|
|
135,643 |
|
|
|
132,417 |
|
|
|
540,704 |
|
|
|
528,845 |
|
% Change |
|
|
2.4 |
% |
|
|
|
|
|
2.2 |
% |
|
|
|
Outpatient Surgery Cases |
|
|
263,832 |
|
|
|
270,286 |
|
|
|
1,024,998 |
|
|
|
1,044,415 |
|
% Change |
|
|
-2.4 |
% |
|
|
|
|
|
-1.9 |
% |
|
|
|
Emergency Room Visits |
|
|
2,498,429 |
|
|
|
2,452,395 |
|
|
|
9,789,265 |
|
|
|
9,342,783 |
|
% Change |
|
|
1.9 |
% |
|
|
|
|
|
4.8 |
% |
|
|
|
Outpatient Revenues as a Percentage of Patient Revenues |
|
|
37.9 |
% |
|
|
38.4 |
% |
|
|
37.8 |
% |
|
|
38.3 |
% |
Average Length of Stay (days) |
|
|
4.814 |
|
|
|
4.911 |
|
|
|
4.841 |
|
|
|
4.920 |
|
Occupancy** |
|
|
71.7 |
% |
|
|
72.5 |
% |
|
|
72.7 |
% |
|
|
72.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Same Facility: |
|
|
|
|
|
|
|
|
|
|
|
|
Admissions |
|
|
552,610 |
|
|
|
536,350 |
|
|
|
2,204,148 |
|
|
|
2,101,839 |
|
% Change |
|
|
3.0 |
% |
|
|
|
|
|
4.9 |
% |
|
|
|
Equivalent Admissions |
|
|
980,330 |
|
|
|
950,949 |
|
|
|
3,881,505 |
|
|
|
3,713,950 |
|
% Change |
|
|
3.1 |
% |
|
|
|
|
|
4.5 |
% |
|
|
|
Revenue per Equivalent Admission |
|
$ |
18,185 |
|
|
$ |
17,674 |
|
|
$ |
17,625 |
|
|
$ |
17,071 |
|
% Change |
|
|
2.9 |
% |
|
|
|
|
|
3.2 |
% |
|
|
|
Inpatient Revenue per Admission |
|
$ |
19,835 |
|
|
$ |
19,006 |
|
|
$ |
19,085 |
|
|
$ |
18,185 |
|
% Change |
|
|
4.4 |
% |
|
|
|
|
|
4.9 |
% |
|
|
|
Inpatient Surgery Cases |
|
|
134,482 |
|
|
|
130,779 |
|
|
|
534,330 |
|
|
|
523,074 |
|
% Change |
|
|
2.8 |
% |
|
|
|
|
|
2.2 |
% |
|
|
|
Outpatient Surgery Cases |
|
|
257,663 |
|
|
|
261,155 |
|
|
|
997,043 |
|
|
|
1,013,752 |
|
% Change |
|
|
-1.3 |
% |
|
|
|
|
|
-1.6 |
% |
|
|
|
Emergency Room Visits |
|
|
2,466,784 |
|
|
|
2,410,050 |
|
|
|
9,642,016 |
|
|
|
9,192,154 |
|
% Change |
|
|
2.4 |
% |
|
|
|
|
|
4.9 |
% |
|
|
|
* Excludes freestanding endoscopy centers (26 centers at December 31, 2024 and 24 centers at December 31, 2023).
** Reflects the rate of occupancy (patient days and observations) based on weighted average beds in service.
HCA Healthcare, Inc.
Supplemental Non-GAAP Disclosures
Operating Results Summary
(Dollars in millions, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter |
|
|
For the Years Ended December 31, |
|
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
Revenues |
|
$ |
18,285 |
|
|
$ |
17,303 |
|
|
$ |
70,603 |
|
|
$ |
64,968 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to HCA Healthcare, Inc. |
|
$ |
1,438 |
|
|
$ |
1,607 |
|
|
$ |
5,760 |
|
|
$ |
5,242 |
|
Losses (gains) on sales of facilities (net of tax) |
|
|
149 |
|
|
|
(9 |
) |
|
|
(11 |
) |
|
|
12 |
|
Net income attributable to HCA Healthcare, Inc., as adjusted (a) |
|
|
1,587 |
|
|
|
1,598 |
|
|
|
5,749 |
|
|
|
5,254 |
|
Depreciation and amortization |
|
|
856 |
|
|
|
789 |
|
|
|
3,312 |
|
|
|
3,077 |
|
Interest expense |
|
|
528 |
|
|
|
491 |
|
|
|
2,061 |
|
|
|
1,938 |
|
Provision for income taxes |
|
|
493 |
|
|
|
486 |
|
|
|
1,863 |
|
|
|
1,608 |
|
Net income attributable to noncontrolling interests |
|
|
248 |
|
|
|
254 |
|
|
|
897 |
|
|
|
849 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA (a) |
|
|
3,712 |
|
|
$ |
3,618 |
|
|
$ |
13,882 |
|
|
$ |
12,726 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA margin (a) |
|
|
20.3 |
% |
|
|
20.9 |
% |
|
|
19.7 |
% |
|
|
19.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to HCA Healthcare, Inc. |
|
$ |
5.63 |
|
|
$ |
5.93 |
|
|
$ |
22.00 |
|
|
$ |
18.97 |
|
Losses (gains) on sales of facilities |
|
|
0.59 |
|
|
|
(0.03 |
) |
|
|
(0.04 |
) |
|
|
0.04 |
|
Net income attributable to HCA Healthcare, Inc., as adjusted (a) |
|
$ |
6.22 |
|
|
$ |
5.90 |
|
|
$ |
21.96 |
|
|
$ |
19.01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing diluted earnings per share (millions) |
|
|
255.310 |
|
|
|
271.186 |
|
|
|
261.806 |
|
|
|
276.412 |
|
(a)Net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles ("GAAP"). These non-GAAP financial measures are adjusted to exclude losses (gains) on sales of facilities and losses on retirement of debt. We believe net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.
Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that adjustments, including losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.
Net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.
HCA Healthcare, Inc.
Supplemental Non-GAAP Disclosures
2025 Operating Results Forecast
(Dollars in millions, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
For the Year Ending |
|
|
|
December 31, 2025 |
|
|
|
Low |
|
|
High |
|
Revenues |
|
$ |
72,800 |
|
|
$ |
75,800 |
|
|
|
|
|
|
|
|
Net income attributable to HCA Healthcare, Inc. (a) |
|
$ |
5,850 |
|
|
$ |
6,290 |
|
Depreciation and amortization |
|
|
3,495 |
|
|
|
3,565 |
|
Interest expense |
|
|
2,230 |
|
|
|
2,320 |
|
Provision for income taxes |
|
|
1,800 |
|
|
|
1,950 |
|
Net income attributable to noncontrolling interests |
|
|
925 |
|
|
|
975 |
|
|
|
|
|
|
|
|
Adjusted EBITDA (a) (b) |
|
$ |
14,300 |
|
|
$ |
15,100 |
|
|
|
|
|
|
|
|
Diluted earnings per share: |
|
|
|
|
|
|
Net income attributable to HCA Healthcare, Inc. |
|
$ |
24.05 |
|
|
$ |
25.85 |
|
|
|
|
|
|
|
|
Shares used in computing diluted earnings per share (millions) |
|
|
243.000 |
|
|
|
243.000 |
|
The Company's forecasted guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.
(a)The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy.
(b)Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles ("GAAP"). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams.
Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our healthcare facilities. Adjusted EBITDA is utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.
Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.
v3.24.4
Document And Entity Information
|
Jan. 24, 2025 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 24, 2025
|
Entity Registrant Name |
HCA Healthcare, Inc.
|
Entity Central Index Key |
0000860730
|
Entity Emerging Growth Company |
false
|
Entity File Number |
001-11239
|
Entity Incorporation, State or Country Code |
DE
|
Entity Tax Identification Number |
27-3865930
|
Entity Address, Address Line One |
One Park Plaza
|
Entity Address, City or Town |
Nashville
|
Entity Address, State or Province |
TN
|
Entity Address, Postal Zip Code |
37203
|
City Area Code |
(615)
|
Local Phone Number |
344-9551
|
Entity Information, Former Legal or Registered Name |
Not Applicable
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.01 par value per share
|
Trading Symbol |
HCA
|
Security Exchange Name |
NYSE
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
HCA Healthcare (NYSE:HCA)
Historical Stock Chart
From Dec 2024 to Jan 2025
HCA Healthcare (NYSE:HCA)
Historical Stock Chart
From Jan 2024 to Jan 2025